• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利斯的明治疗阿尔茨海默病患者。

Rivastigmine in the treatment of patients with Alzheimer's disease.

机构信息

Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Germany.

出版信息

Neuropsychiatr Dis Treat. 2007 Apr;3(2):211-8. doi: 10.2147/nedt.2007.3.2.211.

DOI:10.2147/nedt.2007.3.2.211
PMID:19300554
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2654625/
Abstract

Impairment of attention and memory in patients with Alzheimer's disease (AD) is associated with significantly lower levels of acetylcholine. Inhibition of the breakdown of acetylcholine by blocking the enzymes acetylcholinesterase and butyrylcholinesterase with rivastigmine improves this cholinergic depletion. Thus rivastigmine administration provides established, effective, long-term symptomatic treatment in AD and Parkinson's disease (PD) patients with dementia. A sustained treatment with cholinesterase inhibitors in general may also induce a certain deterioration of fine motor behavior, which may play a crucial role in the treatment of PD patients with dementia. Recent studies show that this altered balance between dopamine and acetylcholine due to cholinesterase inhibition, with its possible negative impact on motion behaviour, does not present a major problem in clinical practice in AD patients and may be compensated for by modification of dopaminergic substitution in PD patients with dementia. However, progression of neurodegeneration increases the vulnerability for psychosis in AD and PD patients with dementia in combination with dehydration and often requires additional application of neuroleptics. Since classical neuroleptics increase extrapyramidal symptoms, atypical neuroleptics are used. Out of these, quetiapine shows a distinct lower anticholinergic (muscarinergic) potency with beneficial effects on cognition. This favors its use in combination with rivastigmine.

摘要

阿尔茨海默病(AD)患者的注意力和记忆力受损与乙酰胆碱水平显著降低有关。通过抑制乙酰胆碱酯酶和丁酰胆碱酯酶来阻止乙酰胆碱的分解,可以改善这种胆碱能耗竭。因此,利凡斯的明在 AD 和帕金森病(PD)伴痴呆患者中提供了已确立的、有效的、长期的症状治疗。胆碱酯酶抑制剂的持续治疗一般也可能导致精细运动行为的一定恶化,这可能在 PD 伴痴呆患者的治疗中起着至关重要的作用。最近的研究表明,由于胆碱酯酶抑制导致的多巴胺和乙酰胆碱之间的这种平衡改变,以及其对运动行为可能产生的负面影响,在 AD 患者的临床实践中并不是一个主要问题,并且可以通过调整 PD 伴痴呆患者的多巴胺替代物来补偿。然而,神经退行性变的进展增加了 AD 和 PD 伴痴呆患者发生精神病的脆弱性,再加上脱水,往往需要额外应用神经安定药。由于经典的神经安定药会增加锥体外系症状,因此使用非典型的神经安定药。在这些药物中,喹硫平显示出明显较低的抗胆碱能(毒蕈碱能)效力,并对认知有有益的影响。这有利于将其与利凡斯的明联合使用。

相似文献

1
Rivastigmine in the treatment of patients with Alzheimer's disease.利斯的明治疗阿尔茨海默病患者。
Neuropsychiatr Dis Treat. 2007 Apr;3(2):211-8. doi: 10.2147/nedt.2007.3.2.211.
2
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.了解和管理阿尔茨海默病及相关痴呆中的行为症状:聚焦于卡巴拉汀。
Curr Med Res Opin. 2002;18(3):156-71. doi: 10.1185/030079902125000561.
3
Rivastigmine for the treatment of dementia associated with Parkinson's disease.利斯的明治疗帕金森病相关痴呆。
Neuropsychiatr Dis Treat. 2007 Dec;3(6):775-83. doi: 10.2147/ndt.s1134.
4
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.卡巴拉汀:乙酰胆碱酯酶和丁酰胆碱酯酶双重抑制的优势及其在皮质下血管性痴呆和帕金森病痴呆中的作用。
Clin Interv Aging. 2017 Apr 18;12:697-707. doi: 10.2147/CIA.S129145. eCollection 2017.
5
Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.用于治疗阿尔茨海默病的胆碱酯酶抑制剂:药理作用与临床疗效之间的关系。
Drugs Aging. 2004;21(7):453-78. doi: 10.2165/00002512-200421070-00004.
6
The ABC of Alzheimer's disease: behavioral symptoms and their treatment.阿尔茨海默病基础知识:行为症状及其治疗
Int Psychogeriatr. 2002;14 Suppl 1:27-49. doi: 10.1017/s1041610203008652.
7
Rivastigmine for Alzheimer's disease.卡巴拉汀用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2015 Apr 10(4):CD001191. doi: 10.1002/14651858.CD001191.pub3.
8
Rivastigmine for Alzheimer's disease.用于治疗阿尔茨海默病的卡巴拉汀
Cochrane Database Syst Rev. 2000(4):CD001191. doi: 10.1002/14651858.CD001191.
9
Rivastigmine for Alzheimer's disease.卡巴拉汀用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2009 Apr 15(2):CD001191. doi: 10.1002/14651858.CD001191.pub2.
10
Rivastigmine for Alzheimer's disease.用于治疗阿尔茨海默病的卡巴拉汀
Cochrane Database Syst Rev. 2000(2):CD001191. doi: 10.1002/14651858.CD001191.

引用本文的文献

1
Resveratrol-Based Carbamates as Selective Butyrylcholinesterase Inhibitors: Design, Synthesis, Computational Study and Biometal Complexation Capability.基于白藜芦醇的氨基甲酸酯类化合物作为选择性丁酰胆碱酯酶抑制剂:设计、合成、计算研究及生物金属络合能力
Molecules. 2025 Jan 15;30(2):316. doi: 10.3390/molecules30020316.
2
Succinimide Derivatives as Acetylcholinesterase Inhibitors-In Silico and In Vitro Studies.琥珀酰亚胺衍生物作为乙酰胆碱酯酶抑制剂的计算机模拟和体外研究
Curr Issues Mol Biol. 2024 May 22;46(6):5117-5130. doi: 10.3390/cimb46060307.
3
Polymeric nanoparticles: A promising strategy for treatment of Alzheimer's disease.聚合物纳米颗粒:治疗阿尔茨海默病的一种有前景的策略。
J Taibah Univ Med Sci. 2024 Apr 26;19(3):549-565. doi: 10.1016/j.jtumed.2024.04.004. eCollection 2024 Jun.
4
Insights into the management of Lewy body dementia: a scoping review.路易体痴呆管理的见解:一项范围综述
Ann Med Surg (Lond). 2024 Jan 3;86(2):930-942. doi: 10.1097/MS9.0000000000001664. eCollection 2024 Feb.
5
Recent Advances in Covalent Drug Discovery.共价药物发现的最新进展
Pharmaceuticals (Basel). 2023 Apr 28;16(5):663. doi: 10.3390/ph16050663.
6
Advances on Therapeutic Strategies for Alzheimer's Disease: From Medicinal Plant to Nanotechnology.阿尔茨海默病治疗策略的进展:从药用植物到纳米技术。
Molecules. 2022 Jul 28;27(15):4839. doi: 10.3390/molecules27154839.
7
Naturally Occurring Antioxidant Therapy in Alzheimer's Disease.阿尔茨海默病的天然抗氧化剂疗法
Antioxidants (Basel). 2022 Jan 23;11(2):213. doi: 10.3390/antiox11020213.
8
In Vitro and In Silico Kinetic Studies of Patented 1,7-diEthyl and 1,7-diMethyl Aminoalkanol Derivatives as New Inhibitors of Acetylcholinesterase.专利的 1,7-二乙基和 1,7-二甲基氨基烷醇衍生物作为乙酰胆碱酯酶新抑制剂的体外和计算动力学研究。
Int J Mol Sci. 2021 Dec 27;23(1):270. doi: 10.3390/ijms23010270.
9
Effect of Leaf Extract on Scopolamine-Induced Memory Deficits in Zebrafish: The Model of Alzheimer's Disease.叶提取物对东莨菪碱诱导的斑马鱼记忆缺陷的影响:阿尔茨海默病模型
Adv Pharmacol Pharm Sci. 2021 Apr 24;2021:6666726. doi: 10.1155/2021/6666726. eCollection 2021.
10
Comprehensive Review on Alzheimer's Disease: Causes and Treatment.阿尔茨海默病的综合综述:病因与治疗。
Molecules. 2020 Dec 8;25(24):5789. doi: 10.3390/molecules25245789.

本文引用的文献

1
Alzheimer's disease.阿尔茨海默病
Lancet. 2006 Jul 29;368(9533):387-403. doi: 10.1016/S0140-6736(06)69113-7.
2
Transdermal treatment options for neurological disorders: impact on the elderly.神经系统疾病的经皮治疗选择:对老年人的影响。
Drugs Aging. 2006;23(5):357-75. doi: 10.2165/00002512-200623050-00001.
3
Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.卡巴拉汀对老年门诊环境中阿尔茨海默病患者认知、日常生活活动能力及行为的治疗效果
Int J Clin Pract. 2006 Jun;60(6):646-54. doi: 10.1111/j.1368-5031.2006.00970.x.
4
Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease.透皮贴剂卡巴拉汀治疗不会使阿尔茨海默病患者复杂运动功能的损害恶化。
Pharmacopsychiatry. 2006 Jan;39(1):16-9. doi: 10.1055/s-2006-931473.
5
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.多奈哌齐、卡巴拉汀和加兰他敏对阿尔茨海默病认知、生活质量及不良事件临床疗效的系统评价。
Int J Geriatr Psychiatry. 2006 Jan;21(1):17-28. doi: 10.1002/gps.1402.
6
Discontinuation of rivastigmine in routine clinical practice.
Int J Geriatr Psychiatry. 2005 Dec;20(12):1167-71. doi: 10.1002/gps.1411.
7
Behavioral and neuropsychiatric outcomes in Alzheimer's disease.阿尔茨海默病的行为和神经精神学转归
CNS Spectr. 2005 Nov;10(11 Suppl 18):22-5. doi: 10.1017/s1092852900014206.
8
Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.卡巴拉汀治疗帕金森病所致痴呆的长期获益:一项活性治疗延长期研究
Mov Disord. 2006 Apr;21(4):456-61. doi: 10.1002/mds.20700.
9
Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.利伐斯的明是阿尔茨海默病斑块和缠结中乙酰胆碱酯酶和丁酰胆碱酯酶的强效抑制剂。
Brain Res. 2005 Oct 26;1060(1-2):144-52. doi: 10.1016/j.brainres.2005.08.039. Epub 2005 Oct 5.
10
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.两年期里,卡巴拉汀与多奈哌齐治疗中度至中度重度阿尔茨海默病。
Curr Med Res Opin. 2005 Aug;21(8):1317-27. doi: 10.1185/030079905X56565.